银屑病关节炎中生物制剂和靶向小分子药物序贯治疗的有效性:一项系统综述
该系统综述检索Medline、Embase等数据库,纳入12篇全文和2篇摘要,评估银屑病关节炎患者在一线之后使用生物制剂和靶向合成改善病情抗风湿药的有效性。多数为观察性研究,偏倚风险高;三项比较一线与二线的研究均发现二线应答降低;DAPSA缓解率随治疗线数增加而下降。作者结论认为b/tsDMARDs在银屑病关节炎至三线可能有效,但一线后应答降低,更后续治疗线数据非常有限,需要前瞻性研究。
要点
- 三项比较一线与二线的研究均发现二线应答降低。
- DAPSA缓解率:TNFi一线26%、二线19%、三线10%;其他bDMARDs一线22%、二线13%、三线11%。
- 至三线bDMARDs应答不一:四项研究二线与三线相当,五项研究序贯线应答递减。
核心结论
- 以观察性研究为主、固有高偏倚风险的证据提示,bDMARDs在银屑病关节炎至三线可能有效,但一线后应答降低。
- 更后续线b/tsDMARDs的数据非常有限,需要前瞻性研究以更好理解晚期治疗线的临床应答。
研究设计与样本
- 系统文献检索Medline、Embase及书目检索(2022年10月和12月),纳入评估成人银屑病关节炎一线之后b/tsDMARDs有效性的研究(PROSPERO CRD42022365298)。
- 共识别2666篇摘要,对177篇银屑病疾病研究进行全文审查后,纳入12篇全文和2篇摘要。
- 12篇全文中11篇为观察性研究、1篇为随机对照试验的亚分析(n=16081:平均年龄49.5岁,女性53.3%);另纳入2篇摘要(n=7186)。
- 采用ROBINS-I/Cochrane RoB2进行偏倚风险评估。
主要发现
- 三项比较一线与二线的研究均发现二线应答降低。
- DAPSA缓解(报告最多的结局,八项研究)平均为:TNFi一线26%、二线19%、三线10%;其他bDMARDs一线22%、二线13%、三线11%。
- 至三线bDMARDs的应答不一:四项研究发现二线与三线应答相当,五项研究发现序贯线应答递减。
局限性
- 以观察性研究为主,固有高偏倚风险(原文自述 predominantly observational studies, inherently at high risk of bias)。
- 更后续线b/tsDMARDs的数据非常有限(原文自述 very limited data)。
- 需要前瞻性研究以更好理解银屑病关节炎晚期治疗线的临床应答(原文自述 Prospective studies are required)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess current evidence for effectiveness of sequential lines of biologic and targeted small-molecule disease-modifying anti-rheumatic drugs (b/tsDMARDs) when used beyond first-line for psoriatic arthritis (PsA). METHODS: A systematic search of the literature (Medline, Embase, bibliographic searches) was undertaken (October and December 2022) to find studies meeting the criteria of assessing effectiveness of b/tsDMARDs beyond first-line in adults with PsA (PROSPERO CRD42022365298). Risk of bias assessment was undertaken (ROBINS-I/Cochrane RoB2). RESULTS: Of 2666 abstracts identified and following a full text review of 177 psoriatic disease studies, 12 manuscripts and two abstracts were eligible. Of the 12 manuscripts, 11 were observational and one was a sub-analysis of a RCT (n = 16 081: average age 49.5 years, female 53.3%). Two abstracts (n = 7186) were included. All studies comparing first- and second-line (three studies) found a reduced response in second-line. On average, DAPSA remission (most reported outcome, eight studies) was achieved in 26%, 19% and 10% first-, second- and third-line TNFi, and 22%, 13% and 11% first-, second- and third-line other bDMARDs, respectively. Responses varied to third-line bDMARDs; four studies found comparable second- and third-line responses, five studies found diminishing responses in sequential lines. CONCLUSION: Predominantly observational studies, inherently at high risk of bias, indicate bDMARDs can be effective to third-line in PsA, but that response is reduced after first line. There is very limited data for more advanced lines of b/tsDMARD. Prospective studies are required to better understand clinical response to advanced lines of treatment in PsA.
引用
- Gollins CE, Vincent R, Fahy C, et al. Effectiveness of sequential lines of biologic and targeted small-molecule drugs in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2024. PMID: 38243715. doi:10.1093/rheumatology/keae006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。